<scp>RNA m<sup>6</sup>A</scp>methylation in cancer

Wang, Zhaotong; Zhou, Jiawang; Zhang, Haisheng; Ge, Lichen; Li, Jiexin; Wang, Hongsheng

doi:10.1002/1878-0261.13326

Cited by 12 publications

(8 citation statements)

References 353 publications

(535 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…65 RNA methylation modifications, mainly including N6adenylation (m6A), N1-adenylate methylation (m1A) and 5-methylcytosine (m5C), are widely existed and involved in the biological processes of cancers. 66,67 m6A methylation modifications are removed by the demethylases (Erasers), including α-ketoglutarate-dependent dioxygenase homologue 5 (ALKBH5), ALKBH3, fat mass and obesity-associated protein (FTO) and other homologies. m6A-binding proteins called 'Readers' recognise these RNAs and perform their functions.…”

Section: Dna/rna Methylation Mediates the Non-coding Rna Expressions ...mentioning

confidence: 99%

Non‐coding RNAs and colitis‐associated cancer: Mechanisms and clinical applications

Zhao

Zheng

et al. 2023

Clinical & Translational Med

View full text Add to dashboard Cite

Background Colitis‐associated cancer (CAC) is one of the most severe complications of inflammatory bowel disease (IBD), which has caused a worse survival rate in IBD patients. Although the exact aetiology and pathogenesis of CAC are not completely elucidated, evidence indicates that non‐coding RNAs are closely involved and play a key role. Methods This review aims to summarise the major findings of non‐coding RNAs in the development of CAC and present the potential mechanistic links between non‐coding RNAs and CAC pathogenesis. The results show that non‐coding RNAs can hinder DNA mismatch repair proteins and obstruct chromosome passenger complexes to increase microsatellite instability and accumulate chromosomal instability, respectively. The data also suggest that DNA promoter methylation or RNA methylation modifications of non‐coding RNA are the main mechanisms to regulate oncogene or tumour suppressor expression during the CAC progression. Other factors, including gut microbiota perturbations, immune dysregulation and barrier dysfunction, are also regulated and influenced by non‐coding RNAs. Besides, non‐coding RNAs as molecular managers are associated with multiple critical signalling pathways governing the initiation, progression and metastasis of CAC, including the janus kinase/signal transducer and activator of transcription (JAK/STAT), nuclear factor‐kappa B (NF‐κB), extracellular signal‐regulated kinase (ERK), Toll‐like receptor 4 (TLR4), Wnt/β‐catenin and phosphatidylinositol 3‐Kinase/Protein Kinase B (PI3K/AKT) pathways. In addition, non‐coding RNAs can be detected in colon tissues or blood, and their aberrant expressions and diagnostic and prognostic roles are also discussed and confirmed in CAC patients. Conclusions It is believed that a deepening understanding of non‐coding RNAs in CAC pathogenesis may prevent the progression to carcinogenesis, and will offer new effective therapies for CAC patients.

show abstract

Section: Dna/rna Methylation Mediates the Non-coding Rna Expressions ...mentioning

confidence: 99%

Non‐coding RNAs and colitis‐associated cancer: Mechanisms and clinical applications

Zhao

Zheng

et al. 2023

Clinical & Translational Med

View full text Add to dashboard Cite

show abstract

“…Sample information on GSE51981 and GSE7305 is detailed in Table 1. Initially, a list of 24 m6A methylation-related genes were assembled from the available published literature and reviews [24][25][26][27][28][29]. Then, the expression levels of these 24 genes were systematically compared in the eutopic endometrium of women with and without EM using the Wilcoxon test in R. A pvalue of < 0.05 was set as the cutoff for differentially expressed genes (DEGs).…”

Section: Study Population Selectionmentioning

confidence: 99%

Profiling N6-methyladenosine (m6A) methylation-related genes in endometriosis towards a diagnostic model

Ying

Yuan

Huang

et al. 2023

Preprint

View full text Add to dashboard Cite

Endometriosis is an inflammatory disease with non-specific symptoms, including chronic pelvic pain and infertility, which affects thousands of women of reproductive age. Early diagnosis of endometriosis remains challenging. We aimed to build a diagnostic model based on m6A methylation-related genes to provide a new perspective on the clinical diagnosis of endometriosis. Two datasets from previous endometriosis studies were selected. GSE51981 was for training and GSE7305 was for validation. The expression of m6A methylation-related genes between proliferative eutopic endometrium from women with and without endometriosis was compared. Most m6A methylation-related genes were down-regulated in eutopic endometrium from women with endometriosis than those without it. The random forest classifier identified 5 significant differentially expressed genes (YTHDF2, NKAP, FTO, ZCCHC4 and HNRNPC) that might be involved in the development of endometriosis by affecting miRNA maturation or immune cell infiltration. These genes were included in a logistic regression to construct a new diagnostic model for endometriosis with an area under the ROC curve of 0.852. The model was tested on another independent dataset（AUC 0.750）and not only diagnosed endometriosis well but also showed how severe it was. We also found that YTHDF2 was very good at diagnosing endometriosis on its own and was correlated with macrophage and neutrophil infiltration that may be important for endometriosis development. In conclusion, this novel diagnostic model using m6A methylation-related genes may be a new method for early non-invasive diagnosis of endometriosis.

show abstract

“…Its abundance underscores its significance in normal physiology. Recent research indicates that aberrant m6A modification is linked to disease pathology, making it a potential therapeutic target 3 …”

Section: Introductionmentioning

confidence: 99%

Targeting RNA modifications with pharmacological agents: New frontiers in cancer therapy

Guan,

Wong

2024

Cancer Medicine

View full text Add to dashboard Cite

The N6‐methyladenosine (m6A) RNA modification has gained significant prominence as a new layer of regulatory mechanism that governs gene expression. Over the past decade, various m6A regulators responsible for introducing, eliminating, and recognising RNA methylation have been identified. Notably, these m6A regulators often exhibit altered expression patterns in cancer, occasionally offering prognostic value. Nonetheless, the complex roles of these regulators in human cancer pathology remain enigmatic, with conflicting outcomes reported in different studies.In recent years, a multitude of inhibitors and activators targeting m6A regulators have been reported. Several of these compounds have demonstrated promising efficacy in both in vitro and in vivo cancer models. These findings collectively underscore the dynamic landscape of m6A regulation in cancer biology, revealing its potential as a therapeutic target and prognostic indicator.

show abstract

RNA m⁶Amethylation in cancer

Cited by 12 publications

References 353 publications

Non‐coding RNAs and colitis‐associated cancer: Mechanisms and clinical applications

Non‐coding RNAs and colitis‐associated cancer: Mechanisms and clinical applications

Profiling N6-methyladenosine (m6A) methylation-related genes in endometriosis towards a diagnostic model

Targeting RNA modifications with pharmacological agents: New frontiers in cancer therapy

Contact Info

Product

Resources

About

RNA m6Amethylation in cancer

Cited by 12 publications

References 353 publications

Non‐coding RNAs and colitis‐associated cancer: Mechanisms and clinical applications

Non‐coding RNAs and colitis‐associated cancer: Mechanisms and clinical applications

Profiling N6-methyladenosine (m6A) methylation-related genes in endometriosis towards a diagnostic model

Targeting RNA modifications with pharmacological agents: New frontiers in cancer therapy

Contact Info

Product

Resources

About

RNA m⁶Amethylation in cancer